Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial

Gerhardt Attard; Matthew R Sydes; Malcolm D Mason; Noel W Clarke; Daniel Aebersold; Johann S de Bono; David P Dearnaley; Chris C Parker; Alastair W S Ritchie; J Martin Russell; George Thalmann; Estelle Cassoly; Robin Millman; David Matheson; Francesca Schiavone; Melissa R Spears; Mahesh K B Parmar; Nicholas D James

doi:10.1016/j.eururo.2014.05.038

Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial

Eur Urol. 2014 Nov;66(5):799-802. doi: 10.1016/j.eururo.2014.05.038. Epub 2014 Jun 27.

Authors

Gerhardt Attard¹, Matthew R Sydes², Malcolm D Mason³, Noel W Clarke⁴, Daniel Aebersold⁵, Johann S de Bono¹, David P Dearnaley¹, Chris C Parker¹, Alastair W S Ritchie⁶, J Martin Russell⁷, George Thalmann⁸, Estelle Cassoly⁹, Robin Millman¹⁰, David Matheson¹¹, Francesca Schiavone⁶, Melissa R Spears⁶, Mahesh K B Parmar⁶, Nicholas D James¹²

Affiliations

¹ The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London and Sutton, UK.
² Medical Research Council Clinical Trials Unit at University College London, London, UK. Electronic address: m.sydes@ucl.ac.uk.
³ Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK.
⁴ Department of Urology, The Christie NHS Foundation Trust, Manchester, UK.
⁵ University of Bern, Bern, Switzerland.
⁶ Medical Research Council Clinical Trials Unit at University College London, London, UK.
⁷ Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁸ Department of Urology, University Hospital, Bern, Switzerland.
⁹ Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland.
¹⁰ Patient representative, Stockton-on-Tees, UK.
¹¹ Patient representative, Northampton, UK.
¹² University of Warwick, Warwick, UK.

PMID: 24985962
DOI: 10.1016/j.eururo.2014.05.038

Abstract

There are compelling reasons to study the addition of both enzalutamide and abiraterone, in combination, to standard-of-care for hormone-naïve prostate cancer. Through a protocol amendment, this will be assessed in the STAMPEDE trial, with overall survival as primary outcome measure.

Trial registration: ClinicalTrials.gov NCT00268476.

Publication types

Editorial
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Androgen Antagonists / administration & dosage
Androstenes / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Benzamides
Cytochrome P-450 Enzyme Inhibitors / administration & dosage
Humans
Male
Neoplasms, Hormone-Dependent / drug therapy*
Neoplasms, Hormone-Dependent / metabolism
Neoplasms, Hormone-Dependent / pathology
Nitriles
Phenylthiohydantoin / administration & dosage
Phenylthiohydantoin / analogs & derivatives
Prednisone / administration & dosage
Prostatic Neoplasms / drug therapy*
Prostatic Neoplasms / metabolism
Prostatic Neoplasms / pathology
Research Design
Steroid 17-alpha-Hydroxylase / antagonists & inhibitors
Steroid 17-alpha-Hydroxylase / metabolism
Switzerland
Treatment Outcome
United Kingdom

Substances

Androgen Antagonists
Androstenes
Benzamides
Cytochrome P-450 Enzyme Inhibitors
Nitriles
Phenylthiohydantoin
enzalutamide
CYP17A1 protein, human
Steroid 17-alpha-Hydroxylase
abiraterone
Prednisone

Associated data

ClinicalTrials.gov/NCT00268476

Abstract

Publication types

MeSH terms

Substances

Associated data

Grants and funding